OnabotulinumtoxinA improves spasticity related pain in post-stroke patients: Findings from a randomized controlled trial  by Wissel, J. et al.
e44 Spasticity / Annals of Physical and Rehabilitation Medicine 57S (2014) e42–e52
J.M. Gracies a,∗, R. Jech b, M. Banach c, P. Valkovic d,
A. Brashear e, P. Mcallister f, H. Walker g, F. Catus h,
C. Vilain h, P. Picaut h
a Hospital Albert Chenevier, Créteil, France
b Neurologicka klinika
c Malopolskie Centrum Medyczne
d II neurologicka klinika
e Wake Forest University Baptist Medical Center
f Southern CT, PC
g Univ of North Carolina, Chapel Hill
h IPSEN INNOVATION
∗Corresponding author.
Background.– This study assessed the efficacy of Abobotulinumtoxin A
(Dysport®) on upper limb spasticity (ULS) and function in hemiparetic adults
following stroke/traumatic brain injury.
Methods.– Phase III, prospective, double-blind, placebo-controlled study; 243
patients (from 34 sites in 9 countries) were randomized (1:1:1) to Dysport® 500
or 1000 units (U) or placebo.
Primary objective.– To assess the efficacy of Dysport® in reducing upper limb
muscle tone (using MAS) in patients’ primary targeted muscle group (finger,
wrist or elbow flexors). Secondary objectives.– Clinical benefit, assessed by
Physician Global Assessment (PGA), and improvement in passive function,
assessed by the Disability Assessment Scale (DAS).
Results.– A significantly higher proportion of patients compared to placebo were
responders:
– ≥ 1 point improvement in MAS as early as 1 week and 4 and 12 weeks post-
injection with either dose of Dysport®;
– significant clinical benefit, according to PGA scale, was also observed.
Similarly, a significantly higher proportion of patients demonstrated ≥ 1 grade
improvement in DAS at week 4 and 12 with 1000 U. No new safety events were
observed.
Conclusions.– Dysport® 500 and 1000 U improved muscle tone and function,
and provided clinical benefit in adults with ULS. Safety profile was consistent
with the known profile of Dysport® in this indication.
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Background.– Botulinum neurotoxin A manages spasticity disorders in neuro-
logical central diseases. But this treatment may induce muscular modifications.
Methods.– We made a literature review in order to explore the structural and
passive biomechanical properties of the musculotendinous unit after injections
in healthy animal muscles and in spastic human muscles, as well as the methods
of evaluation of theses properties.
Results.– Twenty articles have been selected. Histological analyses have
been carried out especially on animals. A neurogenic atrophy systematically
occurs. In humans, one year after a single injection, the histological recovery
is incomplete. The passive biomechanical analysis of muscle stiffness shows
on the short term, a modulus elastic increase in animals whereas no change
is recorded in humans. 2D US analysis shows gastrocnemius thickness and
pennation angle reduce. MRI volumetry analysis shows muscle atrophy, six
months or one year after a single injection. Sonoelastometry analysis shows,
on the short term, a modulus elastic decrease.
Conclusions.– Very little data exists. The muscle changes need to be taken into
account when seeking functional improvement. The protocols are inconsistent.
2D US and Sonoelastometry should be developed in long term monitoring.
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Background.– Patients with upper motor neuron syndrome often experience
spasticity-related pain due to increased muscle tone and flexor/extensor spasms.
Methods.– A total of 274 post-stroke patients with upper and lower limb spas-
ticity were randomized to OnabotulinumtoxinA (BOTOX®) + standard of care
(SC) or saline + SC in the BOTOX® Economic Spasticity Trial’s double blind
phase. Spasticity-related pain was measured using an 11-point pain numeric
rating scale (0 to 10). Change in pain from baseline and proportion of patients
with ≥ 30% improvement were compared between treatment groups using Wil-
coxon rank-sum and chi2 or Fisher’s exact tests.
Results.– Patient’s mean age was 61 years (SD: 11.4); 41% were female. Of 273
patients that received treatment, 202 experienced baseline spasticity-related pain
with the majority (64%) having pain intensity ≥ 4. Among patients with baseline
pain, the mean change in pain at week 12 among OnabotulinumtoxinA + SC
and saline + SC groups were –1.24 (95% CI: –1.8, –0.7) and –0.31 (–0.9, 0.3),
respectively (P < 0.01). The proportion of patients with ≥ 30% improvement was
51% (37/73) for OnabotulinumtoxinA + SC versus 28% (18/65) for saline + SC
(P < 0.01).
Conclusions.– This is the first large RCT showing statistically significant and
clinically meaningful improvement in spasticity-related pain syndromes from
OnabotulinumtoxinA treatment.
http://dx.doi.org/10.1016/j.rehab.2014.03.158
CO41-003-e
Central effects of botulinum neurotoxin A:
Spinal plasticity in stroke patients after
injection in ankle plantarﬂexors
C. Aymard a,∗, V. Marchand-Pauvert b
a Service MPR, Centre Paris Sud, Fondation hospitalière Sainte-Marie, Paris
b ER 6 UPMC, Université Paris 06, Service MPR, Hôpital Pitié-Salpêtrière
∗Corresponding author.
Keywords: Botulinum neurotoxin A; Reciprocal inhibition; Stroke
Background.– BoNT-A depresses recurrent inhibition of lumbar motoneurons
likely due to its retrograde transportation. Because Renshaw cells control group
Ia interneurons mediating reciprocal inhibition between antagonists, we tes-
ted whether this inhibition particularly affected after stroke could recover after
BoNT-A.
Methods.– Effect of posterior tibial nerve stimulation (PTN) on tibialis anterior
electromyogram was investigated in 13 stroke patients during treadmill walking
before and 1 month after BoNT-A injection.
Results.– After injection, the PTN induced reciprocal facilitation in Ia motoneu-
rons during all the swing phase was depressed at the beginning of swing and
reversed into inhibition in midswing.
